Dr. Maha Abu-Khalaf is a medical oncologist specializing in the management of both early-stage and metastatic breast cancer, including inflammatory breast cancer and breast cancer in men. She is actively engaged in clinical trials aimed at evaluating novel therapeutic strategies to improve patient outcomes.
Dr. Abu-Khalaf’s research focuses on understanding the molecular mechanisms underlying resistance to endocrine therapy and CDK4/6 inhibitors in metastatic breast cancer. She has also contributed to clinical investigations assessing the efficacy of PARP inhibitors in patients with BRCA1/2-mutated metastatic breast cancer. Additionally, her work explores the role of social determinants of health in influencing cancer care and outcomes.